- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05091151
Intranasal Dexmedetomidine Sedation at Dose of 2 mcg/kg Versus 4 mcg/kg in Children Undergoing MRI
Comparison of The Effectiveness of Intranasal Dexmedetomidine Sedation at Dose of 2 mcg/kg and 4 mcg/kg in Children Undergoing MRI at Cipto Mangunkusumo Hospital
Study Overview
Status
Intervention / Treatment
Detailed Description
Ninety-four pediatric subjects who would undergo MRI with sedation were recruited. Subjects aged between 1-10 years old, ASA I-II, weighed between 1-30 kg were included in this study and assigned into two groups randomly. One group received 2 mcg/kg (IND2 group) and the other group received 4 mcg/kg (IND 4 group) of intranasal dexmedetomidine.
Randomization was done by the third party, who was not participated in the data collection, by using randomization tool from www.randomizer.org.
Dose of intranasal dexmedetomidine for each participant was concealed using closed envelope and was opened preprocedure by the second party who prepared the sedation drugs. The doctor, who gave sedation drug to the patient and recorded the data, was also blinded. All patients were blinded to data collection. Patients were allowed to drink clear fluid until 2 hours and required to fast for 6 hours before the procedure. Baseline heart rate, SpO2 was recorded premedication.
Subjects in IND 2 and IND 4 group received 2 mcg/kg and 4 mcg/kg intranasal dexmedetomidine. Intranasal drugs were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe. Patient was maintained in supine position for 1-2 minutes to maximize absorption. After the patient was sedated, peripheral intravenous access was performed. The level of sedation was assessed using RSS. Heart rate, oxygen saturation, and RSS are recorded every 10 minutes until the procedure was done. After the target sedation has been reached, MRI started immediately. If the sedation target was not reached and/or the child moved, 0.5 mg/kg rescue dose of propofol would be given. After completing the MRI procedure, the patient was then transferred to the recovery room to record the recovery time. Outpatients were allowed to go home when they reached Aldrete score of 9-10.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
DKI Jakarta
-
Jakarta Pusat, DKI Jakarta, Indonesia, 10430
- Cipto Mangunkusumo General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects aged between 1-10 years old undergoing MRI
- ASA I-II
- Weighed between 1-30 kg
Exclusion Criteria:
- Patients who had history of hypersensitivity reaction to dexmedetomidine or showed an allergic reaction due to sedation drugs during MRI examination.
- Patients with cardiorespiratory, liver, kidney problems, risk of difficult airway, undergoing digoxin or beta blocker therapy, and failed to be sedated after 45 minutes since drug administered.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Intranasal dexmedetomidine at dose of 2 mcg/kg
Subjects in IND 2 group received Intranasal dexmedetomidine at dose of 2 mcg/kg, before the MRI procedure through both nostrils using a 1 mL syringe.
Patient was maintained in supine position for 1-2 minutes to maximize absorption.
|
Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
|
ACTIVE_COMPARATOR: Intranasal dexmedetomidine at dose of 4 mcg/kg.
Subjects in IND 4 group received Intranasal dexmedetomidine at dose of 4 mcg/kg, before the MRI procedure through both nostrils using a 1 mL syringe.
Patient was maintained in supine position for 1-2 minutes to maximize absorption.
|
Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Onset sedation time of Intranasal dexmedetomidine.
Time Frame: 45 minutes before MRI procedure.
|
This study compared the onset time of IND 2 to IND 4 group. Operational definition: Time taken from drug induction to achieve sedation (Ramsay sedation score 5). Ramsay Sedation Scoring system :
|
45 minutes before MRI procedure.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Sedation
Time Frame: During MRI procedure
|
This study compared the duration of sedation of IND 2 to IND 4 group. Operational definition: Time taken from "achieving the sedation target" to "Ramsay's sedation score 3" Ramsay Sedation Scoring system :
|
During MRI procedure
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recovery time
Time Frame: Up to 2 hours after MRI procedure has been completed
|
This study compared the recovery time in IND 2 to IND 4 group. Operational definition: Time calculated from the completion of the MRI procedure until the Aldrete score 9 is achieved (The Aldrete's scoring system is a commonly used scale for determining when patient can be safely discharged from the post-anesthesia care unit. A score of 8-10 is considered adequate to discharge a patient from Phase I of post anesthesia care.) |
Up to 2 hours after MRI procedure has been completed
|
Adverse effect
Time Frame: During MRI procedure dan recovery time
|
This study compared the adverse effect occured in IND 2 to IND 4 group. The acute side effects of sedation, including: Bradycardia (Heart Rate < 60 x/min and/or decrease in HR > 20% from baseline) Desaturation (Moderate desaturation if SpO2 < 95% for 15 seconds, Severe desaturation if SpO2 < 90% for 15 seconds) Allergic reaction (rash, itchy sensation, and hypotension) |
During MRI procedure dan recovery time
|
Rescue dose of Propofol needed
Time Frame: During MRI procedure
|
This study compared the amount of rescue dose of propofol needed in IND2 to IND4 group. This study calculated the amount of rescue dose of propofol needed during the MRI procedure under following conditions: If sedation targets are not achieved, inadequate, or the patient is immobile, boluses of propofol 0.5 mg/kg intravenously could be given to the patient. |
During MRI procedure
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Tug A, Hanci A, Turk HS, Aybey F, Isil CT, Sayin P, Oba S. Comparison of Two Different Intranasal Doses of Dexmedetomidine in Children for Magnetic Resonance Imaging Sedation. Paediatr Drugs. 2015 Dec;17(6):479-85. doi: 10.1007/s40272-015-0145-1.
- Gupta A, Dalvi NP, Tendolkar BA. Comparison between intranasal dexmedetomidine and intranasal midazolam as premedication for brain magnetic resonance imaging in pediatric patients: A prospective randomized double blind trial. J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):236-240. doi: 10.4103/joacp.JOACP_204_16.
- Olgun G, Ali MH. Use of Intranasal Dexmedetomidine as a Solo Sedative for MRI of Infants. Hosp Pediatr. 2018 Jan 23:hpeds.2017-0120. doi: 10.1542/hpeds.2017-0120. Online ahead of print.
- Li BL, Zhang N, Huang JX, Qiu QQ, Tian H, Ni J, Song XR, Yuen VM, Irwin MG. A comparison of intranasal dexmedetomidine for sedation in children administered either by atomiser or by drops. Anaesthesia. 2016 May;71(5):522-8. doi: 10.1111/anae.13407. Epub 2016 Mar 3.
- Schmitz A, Weiss M, Kellenberger C, O'Gorman Tuura R, Klaghofer R, Scheer I, Makki M, Sabandal C, Buehler PK. Sedation for magnetic resonance imaging using propofol with or without ketamine at induction in pediatrics-A prospective randomized double-blinded study. Paediatr Anaesth. 2018 Mar;28(3):264-274. doi: 10.1111/pan.13315. Epub 2018 Jan 27.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- IndonesiaUAnes118
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Magnetic Resonance Imaging
-
BayerCompletedMagnetic Resonance Imaging | Magnetic Resonance AngiographyPoland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
-
Centre Hospitalier Régional Metz-ThionvilleUniversity of LorraineRecruitingMagnetic Resonance ImagingFrance
-
Jessa HospitalActive, not recruitingMagnetic Resonance ImagingBelgium
-
BayerCompletedMagnetic Resonance ImagingUnited States, Korea, Republic of, France, Germany, Italy, Switzerland, United Kingdom
-
Boston Scientific CorporationCompletedMagnetic Resonance ImagingSpain, Hong Kong, Germany, Israel, United Kingdom, Italy, United States, Malaysia, Belgium
-
Centre Hospitalier Universitaire, AmiensCompletedMagnetic Resonance ImagingFrance
-
MegaPro Biomedical Co. Ltd.CompletedMagnetic Resonance ImagingTaiwan
-
BayerCompletedMagnetic Resonance ImagingJapan
-
BayerCompletedMagnetic Resonance ImagingPhilippines
-
BayerCompletedMagnetic Resonance Imaging | Myocardial Perfusion ImagingSwitzerland, Germany, Austria, Poland
Clinical Trials on Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg
-
Protalex, Inc.CompletedArthritis, RheumatoidUnited States
-
Mayo ClinicRecruitingPain ControlUnited States
-
Aretaieion University HospitalCompletedHypertension, Pulmonary | Pulmonary Vascular Resistance Abnormality | Cardiac FailureGreece
-
Milton S. Hershey Medical CenterWithdrawnPneumonia | Acute Respiratory Distress Syndrome | Respiratory Virus Infection
-
University Hospital DubravaRecruitingAortic Valve Stenosis | Systemic Inflammatory ResponseCroatia
-
Baylor College of MedicineCompletedPost Operative Analgesia | Pediatric AdenotonsillectomyUnited States
-
University of ArkansasNot yet recruitingPain | Anxiety | Acute Stress DisorderUnited States
-
Dayton VA Medical CenterWithdrawn
-
Aretaieion University HospitalRecruitingHypertension, Pulmonary | Pulmonary Vascular Resistance Abnormality | Cardiac FailureGreece
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveNetherlands